

Peter Doshi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6130175/publications.pdf>

Version: 2024-02-01

65
papers

2,011
citations

361045

20
h-index

329751

37
g-index

67
all docs

67
docs citations

67
times ranked

2431
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. , 2012, 1, CD008965.		383
2	Neuraminidase inhibitors for preventing and treating influenza in adults and children. The Cochrane Library, 2018, 2018, CD008965.	1.5	328
3	Restoring invisible and abandoned trials: a call for people to publish the findings. BMJ, The, 2013, 346, f2865-f2865.	3.0	153
4	The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience. PLoS Medicine, 2012, 9, e1001201.	3.9	141
5	Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy. Journal of Clinical Epidemiology, 2017, 91, 95-110.	2.4	83
6	Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Health Technology Assessment, 2016, 20, 1-242.	1.3	79
7	Will covid-19 vaccines save lives? Current trials aren't designed to tell us. BMJ, The, 2020, 371, m4037.	3.0	78
8	Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. BMJ Open, 2013, 3, e002496.	0.8	68
9	Rethinking credible evidence synthesis. BMJ: British Medical Journal, 2012, 344, d7898-d7898.	2.4	54
10	Multisystem failure: the story of anti-influenza drugs. BMJ, The, 2014, 348, g2263-g2263.	3.0	50
11	Transparency of COVID-19 vaccine trials: decisions without data. BMJ Evidence-Based Medicine, 2022, 27, 199-205.	1.7	39
12	Harms are assessed inconsistently and reported inadequately part 1: systematic adverse events. Journal of Clinical Epidemiology, 2019, 113, 20-27.	2.4	34
13	Covid-19 vaccines and treatments: we must have raw data, now. BMJ, The, 2022, 376, o102.	3.0	34
14	Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. BMJ: British Medical Journal, 2017, 356, j337.	2.4	30
15	Covid-19 vaccines: In the rush for regulatory approval, do we need more data?. BMJ, The, 2021, 373, n1244.	3.0	30
16	Open data 5 years on: a case series of 12 freedom of information requests for regulatory data to the European Medicines Agency. Trials, 2016, 17, 78.	0.7	26
17	Covid-19 vaccine trial protocols released. BMJ, The, 2020, 371, m4058.	3.0	25
18	The First 2 Years of the European Medicines Agency's Policy on Access to Documents: Secret No Longer. JAMA Internal Medicine, 2013, 173, 380.	2.6	24

#	ARTICLE	IF	CITATIONS
19	The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors. <i>Systematic Reviews</i> , 2018, 7, 117.	2.5	24
20	Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events. <i>Journal of Clinical Epidemiology</i> , 2019, 113, 11-19.	2.4	24
21	Informed Consent to Study Purpose in Randomized Clinical Trials of Antibiotics, 1991 Through 2011. <i>JAMA Internal Medicine</i> , 2017, 177, 1452.	2.6	22
22	Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports. <i>BMJ Open</i> , 2014, 4, e005253-e005253.	0.8	20
23	Influenza: marketing vaccine by marketing disease. <i>BMJ, The</i> , 2013, 346, f3037-f3037.	3.0	19
24	Availability of study protocols for randomized trials published in high-impact medical journals: A cross-sectional analysis. <i>Clinical Trials</i> , 2020, 17, 99-105.	0.7	19
25	Pandemrix vaccine: why was the public not told of early warning signs?. <i>BMJ: British Medical Journal</i> , 0, , k3948.	2.4	17
26	Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol for a systematic review. <i>Systematic Reviews</i> , 2015, 4, 143.	2.5	15
27	Neuraminidase inhibitors for influenza complications. <i>Lancet, The</i> , 2014, 384, 1260-1261.	6.3	14
28	Patient consent to publication and data sharing in industry and NIH-funded clinical trials. <i>Trials</i> , 2018, 19, 269.	0.7	14
29	Challenges of independent assessment of potential harms of HPV vaccines. <i>BMJ: British Medical Journal</i> , 2018, 362, k3694.	2.4	13
30	Influenza Vaccines. <i>JAMA Internal Medicine</i> , 2013, 173, 1014.	2.6	12
31	The end of the pandemic will not be televised. <i>BMJ, The</i> , 2021, 375, e068094.	3.0	12
32	Covid-19: Should doctors recommend treatments and vaccines when full data are not publicly available?. <i>BMJ, The</i> , 2020, 370, m3260.	3.0	11
33	Restoring biomedical literature with RIAT. <i>BMJ: British Medical Journal</i> , 2018, 361, k1742.	2.4	10
34	Transparency Interrupted. <i>JAMA Internal Medicine</i> , 2013, 173, 2009.	2.6	9
35	Oseltamivir for influenza. <i>Lancet, The</i> , 2015, 386, 1134-1135.	6.3	9
36	Integrated Drug Reviews at the US Food and Drug Administration—Legal Concerns and Knowledge Lost. <i>JAMA Internal Medicine</i> , 2020, 180, 629.	2.6	8

#	ARTICLE	IF	CITATIONS
37	North American regulatory agencies can and should make clinical trial data publicly available. <i>Cmaj</i> , 2016, 188, 96-97.	0.9	8
38	Oseltamivir for influenza. <i>Lancet</i> , The, 2016, 387, 124.	6.3	7
39	Canada finally opens up data on new drugs and devices. <i>BMJ: British Medical Journal</i> , 2019, 365, l1825.	2.4	7
40	Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: restoration of previously unpublished methodology. <i>BMJ Evidence-Based Medicine</i> , 2020, 25, 213-219.	1.7	7
41	The Untapped Potential of Pharmacy Leaflets for Informing Patients About Drug Benefits and Risks. <i>JAMA Internal Medicine</i> , 2016, 176, 11.	2.6	5
42	<scp>ADHD</scp> medications and cardiovascular adverse events in children and adolescents: cross-national comparison of risk communication in drug labeling. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 274-284.	0.9	5
43	Communication of Nonefficacy Benefits of New Drugs Approved on the Basis of Noninferiority Trials Alone. <i>JAMA Internal Medicine</i> , 2019, 179, 719.	2.6	5
44	Transparency too little, too late? Why and how Health Canada should make clinical data and regulatory decision-making open to scrutiny in the face of COVID-19. <i>Journal of Law and the Biosciences</i> , 2020, 7, lsa083.	0.8	5
45	Evaluating covid-19 vaccine efficacy and safety in the post-authorisation phase. <i>BMJ</i> , The, 2021, 375, e067570.	3.0	5
46	Digging for data on harms in duloxetine trials. <i>BMJ</i> , The, 2014, 348, g3578-g3578.	3.0	3
47	Neuraminidase Inhibitors and Influenza Infection. <i>JAMA Internal Medicine</i> , 2016, 176, 415.	2.6	3
48	Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling. <i>Journal of General Internal Medicine</i> , 2020, 35, 377-379.	1.3	3
49	Statins for primary prevention: what is the regulator's role?. <i>BMJ Evidence-Based Medicine</i> , 2020, , bmjebm-2019-111321.	1.7	3
50	Is this trial misreported? Truth seeking in the burgeoning age of trial transparency. <i>BMJ</i> , The, 2016, 355, i5543.	3.0	2
51	Disclose Data Publicly, without Restriction. <i>Journal of Law, Medicine and Ethics</i> , 2017, 45, 42-45.	0.4	2
52	Integrated Drug Reviews at the US Food and Drug Administration's Reply. <i>JAMA Internal Medicine</i> , 2020, 180, 1261.	2.6	2
53	Incompletely Reported Important Methodological Details and Inaccurate Description of the Formulation That the Control Arms Received in a Gardasil Vaccine Trial. <i>MSphere</i> , 2020, 5, .	1.3	2
54	Determining the Infectious Potential of Individuals With Positive Reverse-Transcription Polymerase Chain Reaction Severe Acute Respiratory Syndrome Coronavirus 2 Tests. <i>Clinical Infectious Diseases</i> , 2021, 73, e3900-e3901.	2.9	2

#	ARTICLE	IF	CITATIONS
55	Tamiflu reviewers respond to critics. <i>Nature</i> , 2014, 509, 288-288.	13.7	1
56	Safety and Efficacy of Inactivated Influenza Vaccines in Children. <i>Clinical Infectious Diseases</i> , 2015, 60, 489-489.	2.9	1
57	Findings of an Observational Study of Neuraminidase Inhibitors Highly Sensitive to Decision to Exclude 1652 Treated Patients. <i>Clinical Infectious Diseases</i> , 2017, 65, 1050-1050.	2.9	1
58	Assessing Muscle-Related Adverse Events in Randomized Trials of Statins. <i>Journal of General Internal Medicine</i> , 2022, , 1.	1.3	1
59	Authors' reply to Dunning. <i>BMJ, The</i> , 2014, 348, g3018-g3018.	3.0	0
60	The Importance of Influenza Vaccinationâ€”Reply. <i>JAMA Internal Medicine</i> , 2014, 174, 645.	2.6	0
61	The possible harms of statins: What do product labels, patient package inserts, and pharmacy leaflets tell us?. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2019, 59, 195-201.	0.7	0
62	Control vaccine formulation. <i>Lancet, The</i> , 2021, 397, 1061-1062.	6.3	0
63	Contradictory Findings on Efficacy of Neuraminidase Inhibitors Not Cited. <i>Journal of Infectious Diseases</i> , 2020, 222, 1578-1579.	1.9	0
64	Authorsâ€™™ reply to Chiolero, Bannon, and Dickinson. <i>BMJ, The</i> , 2022, 376, o170.	3.0	0
65	Evaluation of Publicly Available Information on Sex-Related Differences in the Efficacy and Safety of Newly Approved Medications. <i>Journal of General Internal Medicine</i> , 2022, , 1.	1.3	0